Company Update (NYSEMKT:MSTX): Mast Therapeutics Inc Announces Initiation of Patient Enrollment in Additional Phase 2 Study of air001 for the Treatment of Heart Failure


mstx2

Mast Therapeutics Inc (NYSEMKT:MSTX) reported that the first patient has been enrolled in an investigator-sponsored Phase 2 study of the Company’s lead product candidate, AIR001, for the treatment of heart failure with preserved ejection fraction (HFpEF). The Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training (INABLE-TRAINING) in HFpEF study will evaluate AIR001’s potential to improve the clinical responses to exercise training in individuals with HFpEF. The INABLE-TRAINING study is expected to enroll approximately 68 patients who will undergo 12 weeks of cardiac rehabilitation, including exercise training, and will be randomized to receive either AIR001 or placebo inhalation solution through the training period. The primary endpoint of the study will be the change in exercise capacity as measured by peak oxygen consumption.

“We are pleased to report that patient enrollment is underway in this Phase 2 study of AIR001 for the treatment of HFpEF,” stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics, Inc. “There are now three Phase 2 studies actively enrolling patients to evaluate AIR001 for the treatment of HFpEF and we remain excited about its potential in this indication. Data from this and other studies will help guide our clinical and regulatory strategy in this area of significant unmet need. Currently, HFpEF affects approximately half of the more than 5 million people in the U.S. diagnosed with heart failure and has no proven effective treatment. Heart failure is a leading cause of morbidity and mortality among the elderly worldwide and is the primary diagnosis in more than 1 million hospitalizations each year, with medical costs projected to rise to more than $50 billion in the U.S. alone by 2030.”(Original Source)

Shares of Mast Therapeutics are currently trading almost flat $0.0839. MSTX has a 1-year high of $0.71 and a 1-year low of $0.07. The stock’s 50-day moving average is $0.09 and its 200-day moving average is $0.37.

On the ratings front, MSTX stock¬†has been the subject of a number of recent research reports. In a report issued on September 27, Cowen analyst Ritu Baral downgraded MSTX to Hold. Separately, on the same day, Laidlaw’s Yale Jen maintained a Hold rating on the stock .

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ritu Baral and Yale Jen have a yearly average return of 1.8% and a loss of 0.4% respectively. Baral has a success rate of 36% and is ranked #1363 out of 4256 analysts, while Jen has a success rate of 42% and is ranked #2809.

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188.